vimarsana.com
Home
Live Updates
NCCN Guidelines Update Adds Momelotinib for High-, Low-Risk
NCCN Guidelines Update Adds Momelotinib for High-, Low-Risk
NCCN Guidelines Update Adds Momelotinib for High-, Low-Risk Myelofibrosis
Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia.
Related Keywords
,
Women Health ,
Digital Health ,
Population Health ,
Nccn Guideline Updates ,
Momelotinib ,
Jak Inhibitors ,
Myelofibrosis ,
Rare Diseases ,